PURPOSE: The therapeutic effect of allogeneic hematopoietic stem cell transplantation (HSCT) for patients with myeloid malignancies has been attributed in part to a graft-versus-leukemia effect that is dependent on donor T lymphocytes. CD8(+) T-cell responses to MHC class I-restricted tumor epitopes, not just allogeneic antigens, may help mediate antileukemia effects after HSCT, but the specificity and function of such cells are not completely understood. EXPERIMENTAL DESIGN: We examined the diversity, phenotype, and functional potential of leukemia-associated antigen-specific CD8(+) T cells in patients with myeloid leukemia following allogeneic HSCT. Screening for antigen-specific T cells was accomplished with a peptide/MHC tetramer library. RESULTS: Patients with acute myelogenous leukemia or chronic myelogenous leukemia in remission following HSCT exhibited significant numbers of peripheral blood CD8(+) T cells that recognized varying combinations of epitopes derived from leukemia-associated antigens. However, these cells failed to proliferate, release cytokines, or degranulate in response to antigen-specific stimuli. As early as 2 months after HSCT, CD8(+) T cells from patients were predominantly CD28(-) CD57(+) and had relatively short telomeres, consistent with cellular senescence. CONCLUSIONS: Circulating leukemia-specific CD8(+) T cells are prominent in myeloid leukemia patients after HSCT, but such cells are largely functionally unresponsive, most likely due to replicative senescence. These findings carry important implications for the understanding of the graft-versus-leukemia effect and for the rational design of immunotherapeutic strategies for patients with myeloid leukemias.
PURPOSE: The therapeutic effect of allogeneic hematopoietic stem cell transplantation (HSCT) for patients with myeloid malignancies has been attributed in part to a graft-versus-leukemia effect that is dependent on donor T lymphocytes. CD8(+) T-cell responses to MHC class I-restricted tumor epitopes, not just allogeneic antigens, may help mediate antileukemia effects after HSCT, but the specificity and function of such cells are not completely understood. EXPERIMENTAL DESIGN: We examined the diversity, phenotype, and functional potential of leukemia-associated antigen-specific CD8(+) T cells in patients with myeloid leukemia following allogeneic HSCT. Screening for antigen-specific T cells was accomplished with a peptide/MHC tetramer library. RESULTS:Patients with acute myelogenous leukemia or chronic myelogenous leukemia in remission following HSCT exhibited significant numbers of peripheral blood CD8(+) T cells that recognized varying combinations of epitopes derived from leukemia-associated antigens. However, these cells failed to proliferate, release cytokines, or degranulate in response to antigen-specific stimuli. As early as 2 months after HSCT, CD8(+) T cells from patients were predominantly CD28(-) CD57(+) and had relatively short telomeres, consistent with cellular senescence. CONCLUSIONS: Circulating leukemia-specific CD8(+) T cells are prominent in myeloid leukemiapatients after HSCT, but such cells are largely functionally unresponsive, most likely due to replicative senescence. These findings carry important implications for the understanding of the graft-versus-leukemia effect and for the rational design of immunotherapeutic strategies for patients with myeloid leukemias.
Authors: Lydie Trautmann; Loury Janbazian; Nicolas Chomont; Elias A Said; Sylvain Gimmig; Benoit Bessette; Mohamed-Rachid Boulassel; Eric Delwart; Homero Sepulveda; Robert S Balderas; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sekaly Journal: Nat Med Date: 2006-08-20 Impact factor: 53.440
Authors: Jochen Greiner; Michael Schmitt; Li Li; Krzysztof Giannopoulos; Katrin Bosch; Anita Schmitt; Konstanze Dohner; Richard F Schlenk; Jonathan R Pollack; Hartmut Dohner; Lars Bullinger Journal: Blood Date: 2006-08-24 Impact factor: 22.113
Authors: C Heining; A Spyridonidis; E Bernhardt; J Schulte-Mönting; D Behringer; C Grüllich; A Jakob; H Bertz; J Finke Journal: Bone Marrow Transplant Date: 2007-03-26 Impact factor: 5.483
Authors: H J Lawrence; S Rozenfeld; C Cruz; K Matsukuma; A Kwong; L Kömüves; A M Buchberg; C Largman Journal: Leukemia Date: 1999-12 Impact factor: 11.528
Authors: Nancy M Hardy; Vicki Fellowes; Jeremy J Rose; Jeanne Odom; Stefania Pittaluga; Seth M Steinberg; Bazetta Blacklock-Schuver; Daniele N Avila; Sarfraz Memon; Roger J Kurlander; Hahn M Khuu; Maryalice Stetler-Stevenson; Esther Mena; Andrew J Dwyer; Bruce L Levine; Carl H June; Ran Reshef; Robert H Vonderheide; Ronald E Gress; Daniel H Fowler; Frances T Hakim; Michael R Bishop Journal: Blood Date: 2012-01-30 Impact factor: 22.113
Authors: Daniel A Zlotoff; Shirley L Zhang; Maria Elena De Obaldia; Paul R Hess; Sarah P Todd; Theodore D Logan; Avinash Bhandoola Journal: Blood Date: 2011-06-09 Impact factor: 22.113
Authors: Simon F Lacey; Corinna La Rosa; Teodora Kaltcheva; Tumul Srivastava; Aprille Seidel; Wendi Zhou; Ravindra Rawal; Katharine Hagen; Aparna Krishnan; Jeff Longmate; Helen A Andersson; Lisa St John; Ravi Bhatia; Vinod Pullarkat; Stephen J Forman; Laurence J N Cooper; Jeffrey Molldrem; Don J Diamond Journal: Blood Date: 2011-06-30 Impact factor: 22.113
Authors: C Berlin; D J Kowalewski; H Schuster; N Mirza; S Walz; M Handel; B Schmid-Horch; H R Salih; L Kanz; H-G Rammensee; S Stevanović; J S Stickel Journal: Leukemia Date: 2014-08-05 Impact factor: 11.528